PRESS RELEASES

​

July 12, 2018 - Ceres Nanosciences’ Point-of-Care Nanotrap® Lyme Antigen Test System Granted Breakthrough Device Designation by U.S. Food and Drug Administration

​

May 31, 2018 - Ceres Nanosciences reaches product development milestone for point-of-care Lyme disease test and closes on an additional $5.5M of Series A funding  

​

December 12, 2017 - Ceres announces major expansion with new Nanotrap® particle manufacturing site in Northern Virginia 

​

September 28, 2017 - Ceres part of team receiving $4.25MM from the DOD to develop a universal surveillance platform for infectious disease outbreaks

​

February 22, 2017 - Ceres receives $750K award from DARPA to adapt Nanotrap® platform to detect Zika and other febrile illnesses

February 2, 2017 - Ceres announces $9MM Series A investment round with initial $3MM investment from GreyBird Ventures

July 6, 2016 - Ceres receives $980K award from DARPA/US Department of Defense to adapt Nanotrap® to capture immune markers from non-invasive samples

​

November 10, 2015 - Ceres Nanosciences announces the publication of pioneering clinical study to develop urine based Lyme Antigen Test. 

June 29, 2015 - Ceres receives $746K from the Bill & Melinda Gates Foundation to use the Nanotrap® to develop a highly sensitive, rapid test for Tuberculosis in urine

March 11, 2015 - Ceres partners with Johns Hopkins to evaluate Nanotrap® saliva test for Malaria

December 2, 2014 - Ceres receives $430K in funding for Ebola test development program from the Bill & Melinda Gates Foundation. Will use Nanotrap® to screen for Ebola Virus in saliva at earliest stages of infection

July 10, 2014 - TGen and Ceres Nanosciences announce collaboration to develop high-throughput Nanotrap® enrichment methods for Mass Spectrometry

July 10, 2013 - Ceres Nanosciences awarded Phase II funding to develop Nanotrap® enhanced detection platform for Rift Valley Fever Virus 

May 30, 2013 - Ceres Nanosciences awarded funding from Virginia Commercialization program to further development of Nanotrap® Universal Sample Collection Toolset 

September 9, 2012 - Ceres Nanosciences awarded DARPA Phase II SBIR to develop Nanotrap® Universal Sample Collection Toolset 

May 23, 2011 - Ceres Nanosciences announces issuance of two Nanotrap® patents 

February 22, 2011 - Ceres Nanosciences awarded 250K to develop Nanotrap® based universal sample preparation tool for Rift Valley Fever Virus 

April 13, 2010 - Ceres Nanosciences completes USADA funded clinical study to measure HGH in urine and establish initial human baseline levels 

April 22, 2009 - Ceres Nanosciences and SAIC-Frederick Collaborate On Cancer Steroid Hormone Studies using Nanotrap® platform

March 1, 2009 - Ceres Nanosciences and USADA Join To Advance Research Aimed at Developing an HGH Urine-Based Test for Benefit of Clean Sport 

July 21, 2008 - Ceres Nanosciences to Develop Nanotechnology Products for Health Care, Industry and Government Applications 

​